Diagnostics company SphingoTec GmbH today announced a publication in Critical Care1 with data on 2,000 ICU patients demonstrating that sphingotec's proprietary biomarker bio-ADM (Bioactive Adrenomedullin) not only identifies high-risk patients for septic shock at admission but also identifies patients in the general ICU patient population who require immediate life-saving therapeutic intervention.
More...